MTIM
ATOS icon

Marathon Trading Investment Management’s Atossa Therapeutics ATOS Stock Holding History

Marathon Trading Investment Management’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-667
Closed -$5.29K – 276
2022
Q4 		$5.29K Hold
667
– – ﹤0.01% 262
2022
Q3 		$8K Hold
667
– – ﹤0.01% 265
2022
Q2 		$11K Hold
667
– – ﹤0.01% 269
2022
Q1 		$13K Buy
+667
New +$13.6K ﹤0.01% 302

Other funds holding ATOS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Laurion Capital Management
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Marathon Trading Investment Management's ATOS Position: Q1 2023 in Review

Marathon Trading Investment Management sold out of Atossa Therapeutics (ATOS) in Q1 2023, closing a stake of 667 shares — an estimated $5.29K sold.

Marathon Trading Investment Management first reported a position in ATOS in Q1 2022 and held it in 4 quarters. The position peaked at $13K in Q1 2022. 45 funds tracked by Wall St. Rank hold ATOS as of Q1 2023.

  • Marathon Trading Investment Management reported no remaining Atossa Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Marathon Trading Investment Management sold 667 Atossa Therapeutics shares in Q1 2023, an estimated $5.29K.
  • Marathon Trading Investment Management first reported a position in Atossa Therapeutics in Q1 2022 and held it in 4 quarters.
  • Marathon Trading Investment Management's Atossa Therapeutics position peaked at $13K in Q1 2022.
  • 45 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q1 2023.

Based on Marathon Trading Investment Management's 13F filing for Q1 2023, filed 12 May 2023.